What are the characteristic clinical features, organ involvement, and laboratory findings of sarcoidosis in young adults?

Features of Sarcoidosis

Sarcoidosis is a multisystem granulomatous disease characterized by nonnecrotizing granulomas, most commonly affecting the lungs (90% of cases) and mediastinal lymph nodes, with highly variable clinical presentations ranging from asymptomatic bilateral hilar adenopathy to life-threatening cardiac and neurologic involvement. 1

Diagnostic Triad

The diagnosis requires three essential components 1:

1. Compatible clinical presentation
2. Nonnecrotizing granulomatous inflammation on tissue biopsy (though not always required for certain pathognomonic presentations)
3. Exclusion of alternative causes of granulomatous disease (infections, malignancy, drug reactions)

Pathognomonic Clinical Syndromes

Certain presentations are so specific they are considered diagnostic without requiring biopsy 1:

• Löfgren's syndrome: Bilateral hilar adenopathy + erythema nodosum and/or periarticular arthritis
• Lupus pernio: Chronic violaceous skin lesions on nose, cheeks, ears
• Heerfordt's syndrome: Fever, parotid enlargement, uveitis, facial nerve palsy

Organ System Involvement

Pulmonary Features (Most Common)

Radiographic findings 1:

• Bilateral hilar adenopathy (70% of patients) - highly probable for sarcoidosis
• Paratracheal lymphadenopathy (40%)
• Perilymphatic nodules on chest CT - highly probable
• Upper lobe or diffuse infiltrates
• Parenchymal nodules (30%), bronchiectasis (25%), ground-glass opacification (18%) 2

Clinical symptoms 3, 2:

• Dyspnea (29%)
• Dry cough (21%)
• Often asymptomatic despite radiographic abnormalities

Pulmonary function abnormalities 4:

• Restrictive pattern (21.6%)
• Obstructive pattern (17.3%)
• Mixed pattern (2.2%)

Extrapulmonary Manifestations

Cutaneous (highly probable features) 1:

• Lupus pernio
• Erythema nodosum
• Maculopapular, erythematous, or violaceous lesions
• Subcutaneous nodules

Ocular (highly probable) 1:

• Uveitis (10.9-20.9% of cases) 4
• Optic neuritis
• Scleritis, retinitis
• Lacrimal gland swelling

Cardiac (high-risk for mortality) 1, 4:

• Cardiac involvement occurs in 2.3-10.7% of cases
• New-onset third-degree AV block in young/middle-aged adults - highly probable
• Ventricular tachycardia without risk factors
• Cardiomyopathy with reduced LVEF
• Leading cause of death from sarcoidosis along with pulmonary disease 5

Neurologic 1:

• Seventh cranial nerve paralysis (probable)
• Optic neuritis (highly probable)
• Gadolinium enhancement on brain MRI (highly probable)

Musculoskeletal 4, 2:

• Arthritis (18% of cases - most common extrapulmonary manifestation)
• Bone involvement: osteolysis, cysts, trabecular pattern (highly probable on imaging)

Hepatosplenic 4:

• Hepatomegaly/splenomegaly (17.6% liver, 20.9% spleen involvement)
• Elevated alkaline phosphatase >3× upper limit of normal (probable)

Lymphatic 4:

• Extrathoracic lymph node involvement (34.2%)

Renal/Metabolic 1:

• Hypercalcemia or hypercalciuria with abnormal vitamin D metabolism (highly probable)
• Nephrolithiasis with calcium stones
• Treatment-responsive renal failure

Histopathologic Features

Classic granuloma characteristics 1:

• Well-formed, compact collections of epithelioid histiocytes
• Multinucleated giant cells centrally
• Outer layer of lymphocytes (mostly T cells)
• Nonnecrotizing (though nodular pulmonary sarcoidosis can show focal necrosis)
• Perilymphatic distribution: around bronchovascular bundles, pleura, septa

Features favoring sarcoidosis 1:

• Numerous discrete granulomas
• Minimal surrounding inflammation
• Fibrosis beginning at periphery extending centrally

Features against sarcoidosis 1:

• Extensive or "dirty" necrosis
• Palisading granulomas
• Robust inflammatory infiltrate
• Positive organism stains/cultures

Laboratory Findings

Supportive but nonspecific 1, 2:

• Elevated ACE (>50% above upper limit) - probable finding, positive in only 16% 2
• BAL lymphocytosis or elevated CD4:CD8 ratio - probable
• Elevated 1,25-dihydroxyvitamin D with normal/low PTH
• Elevated urine calcium (21% of cases) 2
• Polyclonal hypergammaglobulinemia 6

Important caveat: These markers do not correlate with disease severity or treatment need 4 and should not guide treatment decisions.

Clinical Course and Prognosis

Natural history 7:

• Approximately two-thirds show spontaneous remission
• Only 10-30% develop chronic/progressive disease
• Mortality 3-5% overall 7, but 2.4× higher in African American women 1

High-risk phenotypes requiring aggressive monitoring 5, 4:

• Cardiac involvement (sudden death, heart failure)
• Neurologic involvement (irreversible damage)
• Progressive pulmonary fibrosis with pulmonary hypertension
• Multisystem disease (≥5 organs involved in 13.4% of cases) 4

Critical Differential Diagnoses to Exclude

Must rule out 1:

• Tuberculosis (especially in endemic areas) - 38% of alternative diagnoses 1
• Lymphoma - 25% of alternative diagnoses 1
• Chronic beryllium disease (blood lymphocyte proliferation test diagnostic)
• IgG4-related disease (elevated IgG4:IgG ratio in 66%) 6
• Drug-induced granulomatous reactions (checkpoint inhibitors, anti-TNF agents)
• Granulomatosis with polyangiitis (check ANCA antibodies)
• Sarcoid-like reactions to malignancy

Common Pitfalls

1. Assuming bilateral hilar adenopathy is always benign: While 85% of radiographic stage 1 disease is sarcoidosis, 10% can be lymphoma and TB must be excluded 1

2. Over-relying on ACE levels: Only 16% sensitive and does not predict treatment need 2

3. Missing cardiac involvement: Requires specific screening with ECG/Holter at baseline, as it's a leading cause of mortality 5

4. Overlooking hypercalcemia/hypercalciuria: Can cause renal damage; check at diagnosis 8

5. Confusing with IgG4 disease: Elevated IgG4 can occur in sarcoidosis; histopathology differentiates 6